דר׳ קול
מאמרים בספרות המדעית:
Weiner F, Kanter Y, Kol S, Barzilai D. Computer implementation of the new diabetes classification scheme.
Meth Inform Med 21:191, 1982.
Kanter Y, Kol S, Weiner F. Intravenous glucose tolerance test in gestational diabetes and pregnancy: manual vs. computerized assessment.
Eur J Obstet Gynecol Reprod Biol. 27:307, 1988.
Barnea ER, Fares F, Kol S. Stimulatory effect of prolactin on human placental progesterone secretion at term in vitro: possible inhibitory effect on estradiol secretion.
Placenta 10:37, 1989.
Barnea ER, Perlman R, Fakih H, Bick T, Kol S, Hochberg Z. The role of catecholamines in estradiol and progesterone secretion by cultured explants and cells of human term placenta.
Acta Endocrinologica 121:767, 1989.
Barnea ER, Simon RJ, Kol S, Human embryonal extracts modulate placental function in the first trimester: effect of visceral tissues upon chorionic gonadotropin and progesterone secretion.
Placenta 10:331, 1989.
Kol S, Gal D, Friedman M, Paldi E. Case report: preoperative diagnosis of fallopian tube carcinoma by TVS and CA-125. Gynecologic Oncology 37:129, 1990.
Kol S, Jakobi P, Paldi E. The intrauterine device, a transitional period.
Harefua 118:676, 1990.
Adir Y, Bitterman H, Kol S, Melamed Y. Hyperbaric oxygen treatment for carbon monoxide intoxication acquired in the sealed room during the Persian Gulf War.
Israel Journal of Medical Sciences 27:669, 1991.
Barnea ER, Ashkenazy R, Tal Y, Kol S, Sarne Y. Effect of b-endorphin on human chorionic gonadotrophin secretion by placental explants.
Hum Reprod 6: 1327, 1991.
Jakobi P, Kol S, Weissman A, Krivoy N. Peripartum changes in free and protein bound digoxin like immuno-reactive factor.
J Reprod Med 37:127, 1992.
Adir Y, Kol S, Melamed Y. Carbon monoxide and coronary artery disease.
Harefuah, 122:249, 1992.
Nachum Z, Kol S, Adir Y, Melamed Y. Massive air embolism – a possible cause of death after operative hysteroscopy using a 32% dextran 70 pump.
Fertil Steril 58:836, 1992.
Kol S, Ammar R, Weisz G, Melamed Y. Hyperbaric oxygenation for arterial air embolism during cardiopulmonary bypass.
Ann Thorac Surg, 55:401, 1993.
Kol S, Weisz G, Melamed Y. Pulmonary barotrauma after a free dive – a possible
mechanism. Aviat Space Environ Med 64:236, 1993.
Kol S, Levron J, Lewit N, Drugan A, Itskovitz-Eldor J. The natural history of multiple pregnancies after assisted reproduction: Is spontaneous fetal reduction a clinically significant phenomenon?
Fertil Steril 60:127, 1993.
Kol S, Adir Y, Gordon CR, Melamed Y. Oxy-helium treatment of severe spinal decompression sickness after air diving. Undersea Biomed Res 20:147, 1993.
Itskovitz-Eldor J, Levron J, Kol S. Use of GnRH-agonist to cause ovulation and prevent ovarian hyperstimulation sundrome.
Clin Obstet Gynecol, 36:701, 1993.
Aharon-Peretz J, Adir Y, Gordon CR, Kol S. Gal N, Melamed Y. Spinal Decompressionsickness in sport diving.
Arch Neurol 50:753, 1993.
Kol S, Gordon CR, Melamed Y. The potential role of oxygen in the prevention of neurologic deficit after cardiac surgery. Intensive & Critical Care Digest 12:48, 1993.
Payne DW, Shackeleton C, Toms H, Ben-Shlomo I, Kol S, deMoura M, Strauss JF, Adashi EY. A novel nonhepatic hydroxycholosterol 7ahydroxylase that is markedly stimulated by interleukin-1b J
Biol Chem 270:18888-96, 1995.
Kol S, Thaler I, Paz N, Shmueli O. Interpretation of nonstress tests by an artificial neural network.
Am J Obstet Gynecol 172:1372, 1995.
Kol S, Ben-Shlomo I, Adashi EY, Rohan RM. Simplified riboprobe purification using starslucent straws as gel tubes.
Gen Alalysis 1996;12:129-132.
Ben-Shlomo I, Kol S, Ando M, Altman KR, Putowski LT, Rohan RM, Adashi EY Ovarian expression, cellular localization, and hormonal regulation of rat secretory phospholipase A2: increased expression by interleukin-1 and by gonadotropins.
Biol Reprod 1997;57:217-225.
Scherzer WJ, Putowski LT, Kol S, Adashi EY, Rohan RM. Detection and In Vitro Hormonal Regulation of Rat Ovarian Type I and Type II Interleukin-1 Receptor mRNA: Increased Expression During the Periovulatory Period.
J Soc Gyn Invest 1996;3:131-9.
Kol S, Ben-Shlomo I, Ruutianen K, Ando M, Resnick CE, Rohan RM, Adashi EY. The midcycle increase in ovarian glucose uptake is associated with enhanced expression of glucose transporter 3.
J Clin Invest 1997, 99:2274-2283.
Kol S, Ben-Shlomo I, Payne DW, Ando M, Rohan RM, Adashi EY. Glucocorticoids suppress basal (but not interleukin-1-supported) ovarian phospholipase A2 activity: evidence for glucocorticoid receptor-mediated regulation.
Mol Cell Endocrinol 137:117-25, 1998
Ben-Shlomo I, Kol S, Roeder LM, Resnick CE, Hurwitz A, Payne DW, Adashi EY. Interleukin (IL)-1b Increases Glucose Uptake and Induces Glycolysis in aerobically Cultured Rat Ovarian Cells: Evidence that IL-1b may Mediate the Gonadotropin- Induced Midcyle Metabolic Shift. Endocrinology 1997;138:2680-2688.
Kol S, Ben-Shlomo I, Ando M, Payne DW, Adashi EY. Interleukin-1b Stimulates Ovarian Phospholipase A2 (PLA2) Expression and Activity: Up-regulation of Both Secretory and Cystosolic PLA2.
Endocrinology 1997;138: 314-321.
Kol S, Ruutiainen K, Ben-Shlomo I, Ando M, Payne DW, Adashi EY. The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence.
Endocrinology 1997;138:322- 331.
Kol S, Lewit N, Itskovitz-Eldor J. Ovarian Hyperstimulation Syndrome after using Gonadotropin-releasing Hormone Agonist as a Trigger of Ovulation: Causes and implications.
Hum Reprod 11:1143, 1996.
Lewit N, Kol S, Itskovitz-Eldor J. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil Steril 66:654, 1996.
Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of GnRH Analogs And Hcg For The Induction of Ovulation And Preventation of Ovarian Hyperstimulation Syndrome (OHSS): A Case-control Study.
Hum Reprod 11:1399, 1996.
Lewit N, Kol S, Manor D, Itskovitz-Eldor J. The Use of GnRH Analogues For the Induction of Preovulatory Gonadotropin Surge In Assisted Reproduction and Prevention of Ovarian Hyperstimulation Syndrome.
Gynecol Endocrinol 9 (Suppl) 4:13-17, 1995.
Lightman A, Kol S, Wayner V, Vertman D, Manor D, Itskovitz-Eldor J. The presence of a sponsoring embryo in a batch of poor quality thawed embryos significantly increases pregnancy and implantation rate.
Fertil Steril 67:711-6, 1997.
Kol S, Karnieli E, Kraiem Z, Itskovitz-Eldor J, Lightman A, Ish-Shalom S. Thyroid function in early normal pregnancy: transient suppression of thyroid stimulating hormone, and stimulation of triiodothyronine.
Gyncol Obstet Invest 42:227-229, 1996.
Manor D, Kol S, Lewit N, Lightman A, Stein D, Pillar M, Itskovitz-Eldor J. Undocumented embryos: Do not trash them, FISH them.
Hum Reprod 11:2502-2506, 1996.
Itskovitz-Eldor J, Filmar S, Manor D, Stein D, Lightman A, Kol S. Assisted implantation: Direct intra-endometrial embryo transfer.
Gyncol Obstet Invest 43:73- 75, 1997.
Kent-First MG, Kol S, Muallem A, Manor D, Blazer S, First N, Itskovitz-Eldor J. The incidence and possible relevance of Y-linked microdeletions in ICSI derived babies and their infertile fathers.
Mol Hum Reprod 2:943-950, 1996.
Itskovitz-Eldor J, Kol S, Lewit N, Sealey JE. Ovarian origin of plasma and peritoneal fluid prorenin in early pregnancy and in patients with ovarian hyperstimulation syndrome.
J Clin Endocrinol Metab 82:461-464, 1997.
Shupak A, Melamed Y, Ramon Y, Bentur Y, Abramovich A, Kol S. Helium and oxygen treatment of severe air diving-induced neurologic decompression sickness.
Arch Neurol 54:305-311, 1997.
Derman SG, Kol S, Ben-Shlomo I, Resnick CE, Rohan RM, Adashi EY. Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates.
J Endocrinol 160:415-423, 1999.
Kol S, Ben-Shlomo1 I, Ando M, Adashi1 EY. Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression
and activity.
Mol Hum Reprod 1997, 3:1095-1099.
Ando M, Kol S, Kokia E, Ruutiainen-Altman K, Sirois J, Rohan RM, Payne DW, Adashi EY. Rat ovarian prostaglandin endoperoxide synthase-1 and -2: periovulatory expression of granulosa cell-based interleukin-1-dependent enzymes.
Endocrinology 139:2501-8, 1998.
Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink H. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix
(Org 37462).
Hum Reprod 13:294-5, 1998.
Kol S, Ben-Shlomo I, Ando M, Adashi EY. Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression
and activity.
Mol Hum Reprod 3:1095-9, 1997.
Kol S, Donesky BW, Ruutiainen-Altman K, Ben-Shlomo I, Irahara M, Ando M, Rohan RM, Adashi EY. Ovarian Interleukin-1 Receptor Antagonist in Rats: Gene Expression, Cellular Localization, Cyclic Variation, and Hormonal Regulation of a Potential Determinant of Interleukin-1 Action.
Biol Reprod 61:274-282, 1999.
Kol S, Ruutiainen-Altman K, Scherzer WJ, Ben-Shlomo I, Ando M, Rohan RM, Adashi EY. The rat intraovarian interleukin (IL)-1 system: cellular localization, cyclic variation and hormonal regulation of IL-1beta and of the type I and type II IL-1 receptors.
Mol Cell Endocrinol 149:115-28, 1999.
Coffler MS, Kol S, Drugan A, Itskovitz-Eldor J Early transvaginal embryo aspiration: a safer method for selective reduction in high order multiple gestations.
Hum Reprod 14:1875-1878, 1999.
Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, and Itskovitz-Eldor J. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent
freeze–thaw cycles .
Hum Reprod 14:2242-2244, 1999.
Lightman A, Kol S, Itskovitz-Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles.
Hum Reprod 14:2596-2599, 1999.
Ando M, Kol S, Irahara M, Sirois J, Adashi EY. Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL-1 action: implications for the ovulatory process.
Mol Cell Endocrinol 157:21-30, 1999.
Irahara M, Ando M, Kol S, Adashi EY. Expression and hormonal regulation of rat ovarian interleukin-1beta converting enzyme, a putative apoptotic marker: endocrine- and aracrine-dependence.
J Reprod Immunol 45:67-79, 1999.
Kol S, Wong KH, Ando M, Ben-Shlomo I, Adashi EY. Rat ovarian interleukin-1alpha: interleukin-1-dependent in vitro expression.
Endocrine 11:269-75, 1999.
Kol S, Itskovitz-Eldor J. Severe OHSS: Yes, there is a strategy to prevent it!
Hum Reprod 2000 Webtrack (1.8.2000).
Kol S. GnRH antagonists in ART: lower embryo implantation?
Hum Reprod; 5:1881-1882, 2000 Webtrack (12.6.2000).
Lewit N, Kol S. The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up!
Fertil Steril 74:401-2, 2000.
Beloosesky R, Kol S Lightman A, Itskovitz-Eldor J. Ovarian stimulation in in vitro fertilization with or without the “long” gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome.
Fertil Steril 74:166-8, 2000.
Itskovitz-Eldor J, Kol S Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication.
Hum Reprod 15:1965-1968, 2000.
Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it!
Hum Reprod. 15:2266-7, 2000.
Kol S, Should we explore OHSS full clinical scope?…
Hum Reprod. 16:595-6, 2001.
Kol S, Kehat I, Adashi EY. Ovarian interleukin-1-induced gene expression: privileged
genes threshold theory. Med Hypotheses. 58:6-8, 2002. Full text
Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro- alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin.
Fertil Steril 79:1123-8, 2003.
Kol S. Vascular endothelial growth factor – mediator of PHSS?
Fertil Steril 79:1466, 2003.
Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!
Hum Reprod.18:1557-8. 2003.
Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.
Fertil Steril 81:1-5, 2004.
Kol S, Muchtar M. Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further reseach.
Reproductive BioMedicine Online 10:575-577, 2005.
Kol S. To add or not to add LH: consideration of LH concentration changes in individual patients.
Reproductive BioMedicine Online 11:664-666, 2005.
Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?
Journal of Assisted Reproduction and Genetics 25:63-66, 2008.
Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels.
Human Reproducion 23:1004-6, 2008.
Kol S, Dor J. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.
Reproductive BioMedicine Online 19:59-60, 2009.
Kol S, Humaidan P. LH (as hCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango.
Reproductive BioMedicine Online 21:590-592, 2010.
Kol S, Itskovitz-Eldor J. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome–a 20-year experience.
Semin reorod Med 28:500-505, 2010.
Humaidan P, Kol S and Papanikolaou EG, on behalf of the ‘The Copenhagen GnRH Agonist Triggering Workshop Group’. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
Human eproduction Update 2011 ;17:510-524.
Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
Hum. Reprod. 26:2874-77, 2011.
E.G Papanikolaou, P.Humaidan, N. Polyzos, S Kalantaridou, Kol S, C. Benadiva, H.Tournaye, B. Tarlatzis. New algorithm for OHSS prevention.
Reproductive Biology and Endocrinology 2011, 9:14.
P. Humaidan, Kol S, L. Engmann, C. Benadiva, E.G. Papanikolaou, and C. Yding Andersen, on behalf of the Copenhagen GnRH Agonist Triggering Workshop Group. Should Cochrane reviews be performed during the development of new concepts?
Hum. Reprod. 27:6-8, 2012.
Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte
maturation and intensive luteal support.
Hum. Reprod. 27:753-9, 2012.
Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
ACTA Obstetrica et Gynecologica Scandinavica 91:643-7, 2012.
Sella T, Segal Y, Goren I, Chodick G, Shalev V, Homburg R, Bachar R, Kol S. In-Vitro fertilization cycles and outcomes in Maccabi Healthcare Services in Israel 2007-2010.
Harefuah 152:11-14, 2013.
Kol S, Humaidan P. GnRH agonist triggering: recent developments.
Reproductive BioMedicine Online 26: 226– 230, 2013.
Mousavi Fatemi H, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, García-Velasco JA. Severe ovarian hyperstimulation after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze all” approach in GnRH antagonist protocol.
Fertil Steril. 101:1008-11, 2014.
Kol S, Tannus S, Lightman A, Itskovitz J. Assisted reproductive technology in the presence of chronic viral disease.
Harefuah 153:155-158, 2014.
Levron J, Zinchenko V, Kol S, Direnfeld M, Bider D. The use of portable CO2 incubator for cross-border shipping of embryos in an international egg donation program.
Gynecol Endocrinol. 30:755-7, 2014.
Kol S. Individualized Treatment from Theory to Practice: The Private Case of Adding LH during GnRH Antagonist-based Stimulation Protocol.
Clinical Medicine Insights: Reproductive Health 8:59–64, 2014.
Kol S, Humaidan P, Alsbjerg B, Engmann L, Benadiva C, García-Velasco JA, Fatemi H, Andersen CY. The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors.
Reproductive BioMedicine Online 30:563–565, 2015.
Segal L, Breyzman T, Kol S. Luteal phase support post IVF: individualized early stop.
Reproductive BioMedicine Online 31: 633–637, 2015.
Kol S, Breyzman T, Segal L, Humaidan P. ‘Luteal coasting’ after GnRH agonist trigger – individualized, HCG-based, progesterone-free luteal support in ‘high responders’: a case series.
Reprod Biomed Online. 31:747-751, 2015.
Kol S, Breyzman T. GnRH agonist trigger does not always cause luteolysis: a case report.
Reprod Biomed Online. 32:132-134, 2016.
Tannus S, Burke YZ, Kol S. Treatment strategies for the infertile polycystic ovary syndrome patient.
Womens Health (Lond Engl). 11:901-12, 2015.
Kol S, Bergovoy Yellin L, Segal Y and Porath A. In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2007-2014.
Israel Journal of Health Policy Research 5:14, 2016. DOI: 10.1186/s13584-016-0072-9.
Hershkop E, Segal L, Fainaru O, Kol S. ‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic?.
Reprod Biomed Online. 34:274-279, 2017.
Fainaru O, Kol S. How Many Embryos Should Be Transferred? The Relevance of
Parity and Obstetric History.
Isr Med Assoc J. 18:364, 2016
Segal L, Fainaru O, Kol S. Anovulatory Patients Demonstrate a Sharp Decline in LH Levels upon GnRH Antagonist Administration during IVF Cycles.
Rambam Maimonides Medical Journal 8:21, 2017.
Kol S, Fainaru O. GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care Campus.
Rambam Maimonides Medical Journal 8:23, 2017.
Tannus S, Burke Y, McCartney CR, Kol S. GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism.
Gynecol Endocrinol. 25:1-5, 2017.
Vanetik S, Segal L, Breizman T, Kol S. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger – a proof of concept study.
Gynecol Endocrinol. 2018;34:132-135.
Kol S, Gal M. False positive blood hCG test following Corifollitropin alfa injection.
Hum Reprod. 2017 Oct 31:3.
Eshet S, Milner E, Segal L, Monzer A, Kol S. in vitro fertilization (ivf) treatment for viral diseases carriers: summary of treatment outcome of hiv-positive patients.
Harefuah. 2017 Oct;156:670.
Lawrenz B, Humaidan P, Kol S, Fatemi HM. GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?
Reprod Biomed Online. 2018;36:75-77.
Kol S. A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger.
Gynecol Obstet Invest. 2019;84:1-5.
Kol S. Ultra-Orthodox Jews and infertility diagnosis and treatment.
Andrology. 2018;6:662-664 doi: 10.1111/andr.12533.
Shuchat S, Park S, Kol S, Yossifon G. Distinct and independent dielectrophoretic behaviour of the head and tail of sperm and its potential for the safe sorting and isolation of rare spermatozoa.
Electrophoresis. 2019;40:1606-1614.
Kol S, Fainaru O. Inadvertent use of depot GnRH agonist trigger and its effect on the luteal phase. A case report.
Reproductive Medicine International 2018;1:1-2.
Vanetik S, Beck-Fruchter R, Segal L, Kol S. The Importance of Mid-Follicular Phase Luteinizing Hormone Rise in GnRH Antagonist-Based Ovarian Stimulation for IVF.
Gynecol Obstet Invest. 2020;85:184-188.
Kol S. LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective.
Gynecol Obstet Invest. 2020;85:307-311.
Kol S, Segal L. GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte
retrieval for luteal phase support.
Reproductive Biomedicine Online. 2020;41:854-858.
Kol S, Humaidan P. IVF and the exogenous progesterone-free luteal phase.
Curr Opin Obstet Gynecol. 2020 Dec 24.
Humaidan P, Kol S. Suboptimal response to GnRH agonist trigger: causes and practical management.
Curr Opin Obstet Gynecol. 2021 Feb 23.
E. Bosch, C. Alviggi, M. Lispi, A. Conforti, A.C. Hanyaloglu, D. Chuderland, M. Simoni, N. Raine-Fenning, P. Cre´ pieux, S. Kol, V. Rochira, T. D’Hooghe, and P. Humaidan. Reduced FSH and LH action: implications for medically assisted reproduction.
Human Reproduction, 2021.
P. Humaidan, B. Alsbjerg, H.O. Elbaek, B.B. Povlsen, R.J. Laursen, M.B. Jensen, A.T. Mikkelsen L.H. Thomsen, S. Kol, T. Haahr. The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients.
Reprod Biomed Online, Published: March 17, 2021.
S. Kol. Time, time time: see what governs the luteal phase endocrinology.
Gynecological Endocrinology, published: June 4, 2021.
S. Kol P. Humaidan. Luteinizing Hormone and Ovarian Stimulation for In-Vitro Fertilization: Do Science and Business Always Agree? Science Repository, published: August 22, 2022.
J. Castillo, S. Kol. Time-sensitive assessment of luteal phase progesterone after hCG ovulation triggering: Another brick off the wall?
RBMO VOLUME 47, ISSUE5, 2023, 103324.
Castillo J, Quaas AM, Kol S. LH supplementation in IVF: human nature, politics, and elephants in the room.
J Assist Reprod Genet. 2024 Jan 22.
Castillo J, Kol S. Ideal frozen embryo transfer regime.
Curr Opin Obstet Gynecol. 2024 Feb 1.
Orvieto N, segal Y, Kol S. In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2015-2020.
Harefuah, March 2024 (Hebrew).
Kol S, Castillo J, Trolice MP, Quaas AM. Monitoring of controlled ovarian stimulation in IVF.
J Assist Reprod Genet. 2024,41:1715–1717.
פרסומים נוספים, והרצאות בארץ ובחו״ל:
Kol S. First surrogacy pregnancy and delivery in Israel, Maariv, 23.2.1998.
Kol S, Adashi EY. Intra-ovarian factors regulating ovarian function. Current Opinions in Obstetrics and Gynecology, 7:209, 1995.
Kol S, Rohan RM and Adashi EY (2000). The role of growth factors in ovarian function and development. In: Sciarra JJ (Ed.), Gynecology and Obstetrics, Lippincott Williams and Wilkins, Philadelphia, PA. Vol. 5, 11:1-13.
Itskovitz-Eldor J, Kol S. Disorders of the gonadotrophs. In: Reproductive Endocrinology, Surgery and Technology. Adashi EY, Rock JA, Rosenwaks Z Editors, Raven Press, NY (1996).
Kol S, Itskovitz-Eldor J. Triggering ovulation with GnRH analogs. In: Serono Symposia. Ovulation: Evolving Scientific and Clinical Concepts. Eli Y. Adashi, Editor. Springer-Verlag, New York, Inc. 2000, pp. 308-316.
Kol S. Hormonal Therapy of the Infertile Woman. In: “Contemporary Endocrinology: Hormone Replacement Therapy”, second edition. Editor: Wayne Meikle, pp 525-536, 2003, Humana Press, Totowa, NJ.
Kol S. Assisted Reproductive Technology. In: Encyclopedia of Endocrinology and Endocrine Diseases. Editor-in-Chief Luciano Martini, 2004, Academic Press, San Diego. California.
Weissman A, Kol S, Peretz BA. Gas embolism in obstetrics and gynecology. J Reprod Med 41:103-111, 1996.
Kol S, Adir Y, Shupak A, Stahl S. Adjuvant hyperbaric oxygenation therapy in hand edema and ischemia.
\Techniques in Hand and Upper Extremity Surgery 2:274-277, 1998.
Kent-First MG, Kol S, Muallem A, Blazer S, Itskovitz-Eldor J. Infertility in intracytoplasmic-perm-injection-derived sons. Lancet 348:332, 1996.
Kol S. Medical examination of rape victims.
Medicine and Law 15:59, 1996.
Kol S, Lewit N, Itskovitz-Eldor J. Ovarian hyperstimulation syndrome: modern concepts in pathophysiology and management.
Mid East Fertil Soc J 1:246, 1996.
Kol S. Oocyte donation: the shortage and a possible solution. Medicine and Law 19:74-77, 1998.
Fertilization method is linked to gene defect. Washington Post, February 20, 1997.
GnRH agonist instead of hCG to trigger ovulation in GnRH antagonist cycles.
ESHRE Campus, Brussels, December 10th, 2004.
Kol S, Itskovitz-Eldor J. Society’s contribution to assisted reproductive technology abuse.
Hum. Reprod. 20:2362, 2005.
Kol S . Luteal support post GnRH agonist trigger: do not stop too soon.
Human Reproduction 20:3257, 2005.
Kol S. Does ovulation triggering influence the risk of OHSS? In “Ovarian Hyperstimulation Syndrome. Chapter 20.
Edited by Gerris, Olivennes, Delvingne, Taylor&Francis. 2006
Kol S. Agonist trigger in the context of OHSS prevention: primum non nocere.
Human Reproduction Update, advanced access published March 31, 2006.
Kol S. GnRH agonist trigger: looking for the coin under the lamp post?
Human Reproduction 21:1328, 2006.
Prevention of OHSS. Serono Symposia, St. Petersburg, Russia, May 5-6, 2006.
Advanced age fertility: Can we improve the results? The 10th Annual Meeting of the Israeli Society for Community Gynecology, Israel, October 17, 2007.
Kol S Ultrasound-guided embryo transfer – a special role in patients with certain uterine defects.
Fertil Steril. 2008, 89(1):260.
Kol S The vanishing follicle in women aged over forty: Premature, mechanical, LH-independent luteinization may reflect oocyte-follicle low quality?Med Hypotheses. 2008 Jan 10.
R. Homburg, Kol S Letter to the Editor: Reply: Investigating actions of changing hormone levels.
Human Reproduction, doi:10.1093/humrep/den307.
Kol S. Does GnRHa triggering completely abolish OHSS? GnRH agonist for triggering of final oocyte maturation – time for a paradigm shift.
ESHRE Campus, Madrid, Spain, 3 December 2010.
Kol S, Rohan RM and Adashi EY (2008). The role of growth factors in ovarian function and development.
In: The Global Library of Women’s Medicine.
Kol S, A case of severe early-onset OHSS after GnRH-agonist triggering. Letter to the Editor. Fertil Steril. 96:e151, 2011.
Kol S, (2011). Ovarian hyperstimulation prevention.
In: The Global Library of Women’s Medicine.
Kol S, OHSS: Should this be treated or prevented?
Asia Pacific COGI conference, Bangkok, Thailand, November 2011.
P. Humaidan, S. Kol, E.G. Papanikolaou, L. Engmann, C. Benadiva, J. Itskovitz-Eldor, E.J. Margalioth, E. Ricciarelli, D. Bodri, J.C. Castillo-Farfan, J.A. Garcia-Velasco, C. Yding Andersen, P. Devroey and B. Tarlatzis. Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data.
Hum. Reprod. Update 2012 18: 229-230.
Kol S. Prevention of OHSS. Updates in Infertility Treatment, Budapest, Hungary, 8-10 February, 2012.
Kol S. GnRH-a to trigger ovulation should be used in all PCOS patients to prevent OHSS.
COGI conference, Singapore, July 2012.
Kol S. Individualized treatment from theory to practice: the private case of adding LH during GnRH antagonist based stimulation protocol.
11th Internatinal Symposium on GnRH, February 9-11, 2014, Salzburg, Austria.
Kol S.OHSS prevention: Yes, we can! 11th Internatinal Symposium on GnRH, February 9-11, 2014, Salzburg, Austria.
Kol S.IVF 2020, Maccabi Health Care, February 2014.
Kol S. GnRH agonist and individualized luteal phase hCG support will avoid OHSS in PCOS. Toward friendly stimulation in Assisted Reproductive Technology.
Hillel Yafe, Hadera Israel, March 2014.
Kol S. Elonva in poor responders. WOOSP 2014, Jaipur India, August 6-10, 2014.
Kol S. Luteal support post agonist trigger for OHSS prevention: The introduction of “luteal coasting” as a novel approach.. WOOSP 2014, Jaipur India, August 6-10, 2014.
Kol S. Recombinant LH, recombinant hCG and GnRH agonist to trigger ovulation in antagonist cycles: a critical Evaluation.
WOOSP 2014, Jaipur India, August 6-10, 2014.
Kol S. IVF in Israel, quality vs. quantity, Carmel Hospital, Haifa, Israel, October 2014.
Kol S. Treatment strategies for the infertile PCO patient. COGI 2014, Ho Chi Minh City, Vietnam, November 20-22, 2014.
Kol S. Assisted Reproductive Technology (ART), Reference Module in Biomedical Sciences.
Elsevier. 17-Oct-2014 doi:10.1016/B978-0-12-801238-3.03880-0.
Kol S. Luteal coasting post GnRH agonist trigger. COGI 2015, Frankfurt, Germany, May 14-16, 2015.
Kol S. Management of fertility treatment in PCOS patients. Update in Ob/Gyn, Leumit Sick Fund, Dead Sea, Israel, October 9, 2015.
Evron A, Blumenfeld Z, Adashi E, Kol S. The Role of Growth Factors in Ovarian Function and Development.
Glob. libr. women’s med., (ISSN: 1756-2228) 2015; DOI 10.3843/GLOWM.10288.
Kol S. IVF results in Maccabi Health Services 2011-2014.
Research Day, Maccabi-Assuta, Tel Aviv, January 2016 (Hebrew).
Kol S. Regulatory guidelines for IVF: HBV and HCV infected individuals. The ABC for fertility treatments in carriers of hepatitis B&C. Special conference of AYALA, The Israel Fertility Association endorced by the IsASL, The Israel Association for the study of the liver, January 2016, Tel Aviv, (Hebrew).
Kol S. LH and FSH surges for final oocyte maturation: Is dual surge beneficial?. in: Manual of ovulation induction & ovarian stimulation protocols, 3rd edition. Editors: Allahbadia and Merchant.
Jaypee Brothers Medical Publishers, 2016, pp. 463-469.
Kol S. Quality measurement in IVF, Maccabi Health Care, March 2016.
Kol S. TV interview: IVF results in Israel, March 9th, 2016.
Kol S. IVF treatment of high responders. Israel Fertility Association, School of Reproductive Endocrinology, April, 2016.
Kol S. Radio interview: “The experts”, Haifa Radio, June 6th, 2017. link
Kol S. LH supplementation in antagonist protocol, November 17th, 2017. link
Kol S. Reducing implantation failure: novel approach to luteal phase support. Merck organised European Fertility Meeting (PERSONALISING THE PATIENT Journey in ART to SHORTEN TIME TO LIVE BIRTH) November 24th-25th, 2017 at Sheraton Congress Hotel, Frankfurt, Germany.
Kol S. A novel look at luteal phase support post IVF.
XII International Congress on Reproductive Medicine, Moscow, Russia, 16-19.1.2018.
Kol S. The endocrinology of the luteal in IVF. Tel Aviv University, An Update in Fertility Treatments Symposium, June 15th, 2018. link
Kol S. The luteal phase: a new era. Israel Fertility Society meeting, January 2019.
Kol S. The roadmap to LH supplementation in IVF. Sociedade Portuguesa de Medicina da Reprodução. Porto, Portugal, May 10, 2019 (plenary).
Kol S. Prevention of OHSS: Modern Technique. The World Association of Perinatal Medicine, Novel approaches in Fertility and Ovulation, Dead Sea, Jordan, May 25th, 2019 (plenary).
Kol S. Treatment strategies in infertile PCOS. The World Association of Perinatal Medicine, Novel approaches in Fertility and Ovulation, Dead Sea, Jordan, May 25th, 2019 (plenary).
Kol S. Endometrial receptivity can be improved with luteal support fine-tuning. 1st World Congress on Women’s Health Innovations and Inventions (WHII): Addressing Unmet Needs. July 9-11, 2019 Tel Aviv, Israel.
Video clip, IVF Elisha, in Hebrew. link
Working together with the Jewish Fertility Foundation. link
Kol S. What kind and dose of gonadotropins to use? Are biosimilars an option?, EXCEMED, Improving success in ART, Tallinn, Estonia, 19 October 2019. (plenary).
Kol S. Triggering for ovulation – What are the options (hCG, GnRH a, Dual Triggering)?, EXCEMED, Improving success in ART, Tallinn, Estonia, 19 October 2019. (plenary).
Kol S. I-study: Continued medical education, Fertility: Ovulation triggering methods, and luteal phase support, first part. link
Kol S. I-study: Continued medical education, Fertility: Ovulation triggering methods, and luteal phase support, second part. link
Kol S. Natural pregnancy in advanced age (Hebrew). Tel Aviv University, February 21, 2020.
Kol S. The endocrinology of the luteal phase in IVF cycles (Hebrew), IVF Worldwide Webinar Series, April 6, 2020. link
Kol S. Radio Kol Chai interview October 15, 2020 (Hebrew). Listen
Kol S. A wider spectrum in FSH and LH deficiency. The «6th Congress of the Hellenic Society of Fertility & Sterility». Thessaloniki, Greece, May 28-30, 2021, Satellite Symposium 1: Connecting the details for life.
Kol S. LH and FSH deficiency: personalization of controlled ovarian stimulation treatment. Potruguese Fertility Society Annual meeting, Merck symposium. September 24, 2021.
Kol S. Progesterone free luteal support in IVF. IVF Worldwide online congress, October 1-3, 2021.
Kol S. Severe LH and FSH deficiency in an infertile patient undergoing ART. Merck Mini-Symposium, Chateau du Lac, Genval, Belgium 4.10.2021.
Kol S. LH supplementation in ovarian stimulation for IVF: The individual, LH deficient, patient perspective. VITA NOVA 2021 Meeting, Bratislava, Slovakia, 21.10.2021.
Kol S. To add LH or not to add LH? Is this a personal question? 25th Brazilian Congress on Assisted Reproduction and 15th Red Latinoamericana de Reproducción Assistida, November 5, 2021.
Kol S. Poor prognosis patients and LH: from RCT’s and metanalyses to personalized medicine. 9th International IVIRMA Congress, Spain, Virtual Congress Week, November 15-19, 2021.
Kol S. Progesterone-free luteal support for IVF. 17th Annual conference of Indian Fertility Society, FERTIVISION 2021, 10th-12th December, 2021.
Kol S. Individualized LPS: Fresh and FET cycles. Turkish Society of Reproductive Medicine (TSRM): Evidence based approach in ART. September 17, 2022, Ankara, Turkiye.
Kol S. hCG as trigger: The good the bad and the alternative. Ferring Excahnges in Fertility (Scientific Committee), September 29-30, 2022, Copenhagen, Denmark.
Kol S. To add LH or not to add LH during ovarian stimulation, video clips, Buenos Aires Argentina, March 2022. links.
Kol S. LH supplementation and ART: For whom? Ho Chi Minh City, Vietnam, November, 2022.
Kol S. Time to personalize luteal phase support – fresh and FET cycles. Cappadocia, Turkiye, May 2023.
Kol S. Individualized LH supplementation in ovarian stimulation for IVF: Just a slogan or a reality. Athens, Greece, July, 2023.
Kol S. LH supplementation in IVF: It is all about endocrinology. Tartu. Estonia, 20.10.23.